Inexperienced vitality inventory beneath ₹ 50 that elevated its market share to 27% in wind generators 


The shares of one of many main international renewable vitality resolution suppliers have surged by 330% over the previous 12 months. This firm’s market share in wind generator manufacturing has risen from 22% to 27%. It’s labeled as a large-cap inventory. 

Suzlon Vitality Ltd., an end-to-end wind energy options provider in India, manufactures wind turbine mills, energy era gear, and associated gear., Suzlon is a market chief with 111+ wind farms and an put in capability of over 14,490 MW. 

The corporate is a renewable vitality options supplier and is within the enterprise of producing, mission execution, and operation and upkeep of wind turbine mills, and sale of associated parts. 

Word: If you wish to be taught Candlesticks and Chart Buying and selling from Scratch, right here’s the very best ebook out there on Amazon! Get the ebook now!

Over the previous 20 years, Suzlon has put in over ~20.5 GW of wind vitality in 17 international locations throughout six continents 

Over the previous three years, it has diminished its debt from Rs 12,000 crore in FY20 to nil in FY24 by means of numerous debt-to-equity conversions. 

The corporate has lately develop into web money optimistic with a money reserve of Rs 11bn as of Mar’24, after an fairness raises price Rs 2,000 crore in Q2FY24 for debt discount. 

Suzlon Vitality Ltd., the wind turbine generator producer, has elevated its market share to 27% within the monetary yr 2024 from 22% in monetary yr 2023. 

The Suzlon Group CFO additional added that from a product perspective, Suzlon has a transparent lower USP.Suzlon has a aggressive fringe of the one turbine that’s designed particularly for Indian circumstances. 

The corporate’s Product Profile consists of S144 Wind Turbine Generator and S133 Wind Turbine Generator and S120 Wind Turbine Generator and Traditional Fleet.Firm has phased out the manufacturing of its older WTG fashions – S111, S97, S88, S82, S66, and S52. 

Suzlon lately secured its first order for the fiscal yr 2025, totaling 402 MW, from Juniper Inexperienced Vitality.The corporate’s income elevated by 9.5% year-over-year, from Rs 5,971 crore in FY 21-22 to Rs 6,529 crore in FY 22-23. Nevertheless, its web revenue declined by 77%, from Rs 2,887 crore to Rs 660 crore. 

As of FY24, Suzlon holds its largest ever order ebook of three.3 GW and has a web money place of Rs 1,148 crore as of March 31, 2024. Throughout the identical interval, the corporate launched the S144 – 3.x MW collection.

Himanshu Mody, Chief Monetary Officer of Suzlon Group, emphasised the corporate’s dedication to sustaining a cost-conscious method and prioritizing the well timed execution of its order ebook. He additionally highlighted Suzlon’s wide-ranging digitization initiatives geared toward unlocking worth throughout its companies, notably within the service sector. 

Within the newest shareholding sample, the corporate’s promoter holds a 13.28% stake, home institutional traders (DII) maintain a 6.30% stake, and overseas institutional traders (FII) maintain a 19.57% stake. 

Suzlon Vitality Ltd shares have gained 13% over the past six months and 330% over the past 12 months. 

Suzlon’s consumer base consists of distinguished corporations akin to ACC, Adani Renewables, Aditya Birla Group, Bajaj, GAIL, Hero, ITC, ONGC, Reliance, SBI, Tata, TVS, and Vedanta. 

Primarily based on the corporate’s robust outlook, ICICI Securities has revised its goal worth to Rs 54 per share, citing strong order influx and mission execution progress. 

The brokerage revised its FY26 estimates for Suzlon Vitality following a powerful order influx of three.5 GW in This autumn FY24, resulting in an order backlog of three.3 GW. It adjusted the FY26 EBITDA estimate by 5% to Rs 2,750 crore and the revenue estimate by 11% to Rs 2,100 crore. 

On Tuesday, Suzlon’s shares closed at Rs 44 per share, representing a 2.65% lower from the earlier closing worth. The corporate’s market worth now stands at Rs 59,372 crore. 

Written by Omkar Chitnis


The views and funding ideas expressed by funding consultants/broking homes/score companies on are their very own, and never that of the web site or its administration. Investing in equities poses a danger of monetary losses. Buyers should subsequently train due warning whereas investing or buying and selling in shares. Dailyraven Applied sciences or the writer are usually not accountable for any losses prompted because of the choice based mostly on this text. Please seek the advice of your funding advisor earlier than investing.

Leave a Reply

Your email address will not be published. Required fields are marked *